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Abstract
Summary The influence of age and sex steroids on bone
density and geometry of the radius was examined in two
European Caucasian populations. Age-related change in
bone density and geometry was observed. In older men,
bioavailable oestradiol may play a role in the maintenance
of cortical and trabecular bone mineral density (BMD).
Introduction To examine the effect of age and sex steroids
on bone density and geometry of the radius in two
European Caucasian populations.
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Osteoporos Int (2011) 22:1513–1523Methods European Caucasian men aged 40–79 years were
recruited from population registers in two centres: Man-
chester (UK) and Leuven (Belgium), for participation in the
European Male Ageing Study. Total testosterone (T) and
oestradiol (E2) were measured by mass spectrometry and
the free and bioavailable fractions calculated. Peripheral
quantitative computed tomography was used to scan the
radius at distal (4%) and midshaft (50%) sites.
Results Three hundred thirty-nine men from Manchester and
389 from Leuven, mean ages 60.2 and 60.0 years, respec-
tively, participated. At the 50% radius site, there was a
significant decrease with age in cortical BMD, bone mineral
content (BMC), cortical thickness, and muscle area, whilst
medullary area increased. At the 4% radius site, trabecular
and total volumetric BMD declined with age. Increasing
bioavailable E2 (bioE2) was associated with increased
cortical BMD (50% radius site) and trabecular BMD (4%
radius site) in Leuven, but not Manchester, men. This effect
was predominantly in those aged 60 years and over. In older
Leuven men, bioavailable testosterone (Bio T) was linked
with increased cortical BMC, muscle area and SSI (50%
radius site) and total area (4% radius site).
Conclusions There is age-related change in bone density and
geometry at the midshaft radius in middle-aged and elderly
European men. In older men bioE2 may maintain cortical
and trabecular BMD. BioT may influence bone health
through associations with muscle mass and bone area.
Keywords Ageing.Epidemiology.Osteoporosis.
Peripheral quantitative computed tomography.Sex
hormones
Introduction
Osteoporosis in men is an increasing but under-appreciated
clinical and public health problem with the lifetime
risk of fracture in men at age 50 years estimated at
21% [1]. As in women, increasing age is one of the major
determinants of osteoporosis and fracture risk in men.
Most studies examining changes in bone health with age
have focused on “areal” bone mineral density (g/cm
2;
BMDa)[ 2] as measured by dual-energy X-ray absorp-
tiometry (DXA) [3–6]. There are limitations, however, in
assessment of bone health using DXA. In particular,
DXA tends to overestimate BMD in larger, and under-
estimate in smaller, bones. Furthermore, bone strength
and susceptibility to fracture is influenced not only by
the bone mineral content (BMC) but also bone shape and
mineral distribution and the loading conditions to which
the bone is subjected. Peripheral quantitative computed
tomography (pQCT) allows assessment of both bone
geometry and material properties including volumetric
density (BMD). In contrast to age-related changes in DXA
BMDa in men there are relatively few data concerning
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Osteoporos Int (2011) 22:1513–1523 1514change in BMD as assessed by pQCT and bone structure
with age.
Levels of sex steroids are known to be associated with
BMDa, as assessed using DXA, and also rate of bone loss
[7–13]. The contribution of oestradiol (E2) to BMD has
been reasonably well established but the effect of testoster-
one (T) is less clear, as are the effects of sex hormones on
bone structural parameters. Khosla et al. [9, 14] showed
that oestradiol (E2) was the most constant predictor of
BMD and geometry, measured by QCT, with the effect
being more marked in elderly men as age-related declines
in sex steroids become relevant. Similarly in the MINOS
cohort, E2 was related to DXA BMDa cortical thickness and
area [15]. There is some evidence to suggest a threshold
effect of oestrogen, particularly in cortical bone, below
which the male skeleton may suffer oestrogen-related bone
loss similar to that in the post menopausal female—the
threshold level being the median value of bioavailable (bio)
E2 (<30 pM) in older (>60 years) men [8, 14]. Testosterone
(T) has been linked with cortical and trabecular BMD [14,
16] with conflicting data on effects on bone geometry.
Some studies have observed an association between
testosterone and bone loss in males [13] whilst others have
shown little or no effect, be it assessing BMDa or increased
fracture risk [15, 17–19]; geometric parameters were not
reported in these studies.
The aims of this cross-sectional study were: firstly to
determine the influence of age on BMD and bone structure
at the radius in middle-aged and elderly European men;
secondly to determine the relationship between BMD and
bone structure with sex steroid levels, and thirdly to
determine whether the strength of any association between
bioE2 and BMD differ above and below a threshold level of
bioE2 defined as the median value among older men
(60 years and over).
Materials and methods
Subjects
The subjects included in this analysis were recruited for
participation in the European Male Ageing Study
(EMAS), a prospective study of ageing in European
Caucasian community-dwelling men. Detailed methods
have been described previously [20]. Briefly, men were
recruited from population-based sampling frames in eight
centres between 2003 and 2005. Stratified random
sampling was used with the aim of recruiting equal
numbers of men in each of four 10-year age bands: 40–
49 years, 50–59 years, 60–69 years, and 70–79 years.
Letters of invitation were sent to subjects asking them to
attend for health assessments by a range of health
questionnaires, physical and cognitive performance tests,
anthropometry and a fasting blood sample. In two centres,
Manchester (UK) and Leuven (Belgium) subjects had
pQCT measurements performed at the radius. Ethics
approval for the study was obtained in accordance with
local institutional requirements in each centre, and each
participant gave written informed consent.
Peripheral quantitative computed tomography
Peripheral QCT measurements of the non-dominant radius
were made in men recruited to the Manchester and
Leuven centres using XCT-2000 scanners (Stratec, Pforz-
heim, Germany). At the distal (4%) site total and
trabecular BMD (mg/cm
3) and bone cross-sectional area
(mm
2) were measured (voxel size, 0.4 mm); the slice
location at the 4% and 50% site was more distal in Leuven
compared with Manchester; the reference line was placed at
the distal border of the radial endplate in Leuven, in
Manchester the line is placed to bisect the lateral border of
the endplate these differences result in a scan site difference
approximately 1–2 mm between centers. At the diaphysis
(50% site, voxel size 0.6 mm), cortical BMD (mg/cm
3),
cortical BMC (mg/mm), total, cortical and medullary areas
(mm
2), cortical thickness (mm), stress strain index (SSI,
mm
3) and muscle cross-sectional area, as a proxy for
muscle strength (CSMA, mm
2), were measured. SSI
provides a measure of a bone’s torsional strength [21, 22].
Table 1 Subject characteristics: by centre
Variable Manchester
N=339
Leuven
N=389
Mean (SD) Mean (SD)
Age at interview (years) 60.2 (11.1) 60.0 (11.1)
Height (cm) 174.3 (7.2) 174.5 (7.1)
Weight (kg) 83.8 (13.4) 82.1 (13.2)
Body mass index (kg/m
2) 27.5 (3.6) 26.9 (3.9)*
Midshaft radius
Cortical BMD (mg/cm
3) 1,149.8 (39.8) 1,161.0 (38.0)*
Cortical BMC (mg/mm) 120.5 (18.0) 124.0 (17.2)*
Total area (mm
2) 149.5 (21.5) 150.5 (22.3)
Cortical thickness (mm) 3.2 (0.5) 3.2 (0.4)
Medullary area (mm
2) 43.4 (17.2) 43.7 (18.9)
Cross-sectional muscle area (mm
2) 3,558.3 (649.3) 3,744.8 (591.6)*
Stress strain index (mm
3) 330.3 (63.4) 345.6 (67.1)*
Distal radius
Total density (mg/cm
3) 436.3 (70.1) 361.1 (57.3)*
Total area (mm
2) 341.2 (52.5) 413.1 (66.7)*
Trabecular density (mg/cm
3) 203.9 (48.0) 205.5 (41.4)
*p<0.05
Osteoporos Int (2011) 22:1513–1523 1515A detailed methodology for these measurements has been
described previously [23].
For cross-calibration between Leuven and Manchester
the European Forearm Phantom (EFP) was measured [24];
10 repeat measurements were taken in slices 1–4. There
were no differences greater than precision error for
trabecular, total and cortical BMD, BMC or cortical area.
Therefore no cross-calibration was performed between
the two centres. These data and decisions were reviewed
by Dr Klaus Engelke a CT expert from University of
Erlangen, Germany and the scanner manufacturer Stratec
Medizintechnik GmbH, Profzheim, Germany (Dr. Johannes
Willnecker—personal communication).
The short term precision of two repeat radius measure-
ments with repositioning in adults were: Manchester (n=22)
Leuven (n=40) trabecular BMD 1.27%, 1.42%; total BMD
2.1%, 1.3%; cortical BMD 0.77%, 0.71%; cortical area
2.4%, 1.3%; muscle area 3.7%, 1.1%. Manufacturer’s
standard quality assurance procedures were followed in both
centres.
Sex hormone measurement
A single-fasting morning (before 10.00 h) venous blood
sample was obtained from all subjects. Serum was
separated immediately after phlebotomy and stored at
−80°C until assay at the end of the baseline study.
Measurement of T and E2 were carried out by gas
chromatography mass spectrometry as described in Labrie
et al. [25, 26]. The lower limit of T quantitation was
0.17 nmol/L and E2 was 7.34 pmol/L. The coefficients of
variation of T measurements were 2.9% within runs and
3.4% between runs, and for E2, were 3.5% within runs and
3.7% between runs. SHBG was measured by the Modular
E170 platform electrochemiluminescence immunoassay
(Roche Diagnostics, Mannheim, Germany) as previously
described [27]. Free and bioT and E2 levels were derived
from total T, total E2, SHBG, and albumin concentrations
using mass action equations and associations constants of
Van Pottelbergh et al. and Vermeulen et al. [12, 28].
Table 2 Sex hormone descriptives: by centre
Variable Manchester
N=339
Leuven
N=389
Mean (SD) Mean (SD)
Testosterone (nmol/L) 17.3 (6.2) 18.6 (5.9)*
Free testosterone (pmol/L) 306.1 (91.1) 324.8 (88.6)*
Bioavailable testosterone (nmol/L) 7.6 (2.3) 8.2 (2.3)*
Oestradiol (pmol/L) 80.4 (25.7) 73.5 (24.2)*
Free oestradiol (pmol/L) 1.4 (0.4) 1.2 (0.4)*
Bioavailable oestradiol (pmol/L) 56.4 (18.0) 51.2 (17.0)*
SHBG (nmol/L) 42.0 (18.2) 43.7 (19.2)
Reference range in healthy men aged 18–29 years for total
testosterone measured by mass spectroscopy (MS) is 9–42 nmol/L
and for calculated free testosterone 146–555 pmol/L [36]. There are at
present no published reference ranges for oestradiol measured by MS
in healthy young men. Reference range in healthy men aged 20 years
for SHBG measured by immunoassay is 13–53 nmol/L [37]
*p<0.05
Table 3 Influence of age on pQCT parameters at the radius: by centre
Manchester Leuven
β co-efficient
a (95% CI) % change/year β co-efficient
a (95% CI) % change/year
Midshaft radius
Cortical BMD −1.210 (−1.573, −0.846)* −0.107 −0.894 (−1.225, −0.562)* −0.077
Cortical BMC −0.290 (−0.462, −0.119)* −0.271 −0.260 (−0.414, −0.108)* −0.208
Total area 0.176 (−0.032, 0.384) 0.119 0.060 (−0.142, 0.261) 0.040
Cortical thickness −0.010 (−0.014, −0.005)* −0.319 −0.007 (−0.010, −0.003)* −0.219
Medullary area 0.310 (0.147, 0.473)* 0.824 0.206 (0.036, 0.375)* 0.471
Stress strain index −0.022 (−0.637, 0.593) −0.021 −0.510 (−1.114, 0.094) −0.148
CSMA
b −20.561 (−26.464, −14.658)* −0.567 −14.763 (−19.908, −9.618)* −0.394
Distal radius
Total density −1.847 (−2.498, −1.196)* −0.446 −1.665 (−2.157, −1.172)* −0.461
Total area 0.413 (−0.094, 0.921) 0.114 0.501 (−0.102, 1.103) 0.121
Trabecular density −0.676 (−1.137, −0.216)* −0.397 −0.452 (−0.825, −0.079)* −0.220
*p<0.05
aChange in each pQCT parameter per 1 year increase in age
bCross-sectional muscle area
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Linear regression was used to explore the association
between age and various pQCT parameters as dependent
variables; and the results expressed as unstandardised β
coefficients and 95% confidence intervals. Regression
analysis was also used to investigate the association
between pQCT parameters and sex hormones (analysed as
continuous variables) including total, free and bioavailable
E2 and T. Adjustments were made in these analyses for age,
a
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Fig. 1 a Association between
cortical BMD at the midshaft
radius and age: by centre. b
Association between stress
strain index at the midshaft
radius and age: by centre. c
Association between
cross-sectional muscle area at
the midshaft radius and age: by
centre. d Association between
total density at the distal radius
and age: by centre
Osteoporos Int (2011) 22:1513–1523 1517height and weight as these variables were found to have
significant independent associations with the pQCT param-
eters. We tested for a centre interaction for the hormone and
pQCT regressions. For some parameters, there was a
significant interaction and therefore our analyses were
performed in each centre separately. Based on previous
data suggesting an influence of age on the association
between sex hormone status and pQCT parameters, the
analysis was repeated after stratification by age (<60 and
>60 years) [14]. Subjects were categorised into those above
or below a bioE2 threshold, defined as the median value in
those over 60 years (51 pmol/L) and the association
between bioE2 and BMD measurements (at both 4% and
50% sites) examined. All data from the two centres were
analysed separately. Statistical analysis was performed
using STATA version 9.2 (http://www.stata.com).
Results
Subject characteristics
Threehundredthirty-ninemenfromManchesterand389from
Leuven participated in this study. Their mean ages were 60.2
and 60.0 years, respectively. There were no differences in
height orweightbetweensubjectsrecruited in the twocentres,
but body mass index was slightly greater in Manchester (27.5
vs 26.9 kg/m
2), see Table 1. Cortical BMD and BMC at the
midshaft, and also cross-sectional muscle area and SSI were
significantly greater in subjects recruited in Leuven, Table 1.
At the distal radial (4%) site, radial area was greater in
Leuven and total BMD lower in Leuven compared to
Manchester, indicating the slightly different scan location
(in more distal thus expanded radius site in Leuven).
Sex hormone levels in the different centres are presented
in Table 2. The mean serum T levels (total, free and
bioavailable) were higher in Leuven than Manchester while
the total, free and bioavailable E2 levels were lower. There
was no difference in SHBG levels in the two centres.
Age-related variations in bone mass and geometry
At the 50% midshaft site, lower cortical BMD, BMC,
thickness and muscle area, and greater medullary area were
decreased with age. There were no age-related variations
in bone strength as assessed by SSI, (Table 3,F i g .1)a t
either study centre. There were small though non-
significant increases in bone area with age. For all
parameters the change with age was broadly linear across
the age range with no evidence of accelerated loss in later
life. At the distal radius, there was a negative association
of both trabecular and total BMD with age in both centres,
Fig. 1.
Influence of sex hormones on pQCT parameters
The association between total, free, and bioavailable
fractions of T and E2 with pQCT parameters were broadly
similar. We present data here for the bioavailable
hormone relationships (bioE2, bioavailable testosterone
(bioT)) (Table 4). In Leuven men, higher bioE2 was
associated with increased cortical BMD at the 50% site
and trabecular BMD at the 4% site; higher bioE2 was
associated also with greater cortical thickness and smaller
medullary area. There was no important effect of bioT on
BMD at either site. BioT was positively associated with
CSMA in the Leuven men. There were no significant
associations with any of the skeletal parameters in the
Manchester men other than a negative association between
total area (4% site) and bioE2. Based on previous data [14]
suggesting an influence of age on the association between
sex hormone status and pQCT parameters, we analysed
men above and below 60 years separately. The data are
presented in Table 5. In Leuven men, all the significant
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Osteoporos Int (2011) 22:1513–1523 1518associations observed in the unstratified analysis were
observed exclusively in the older men. Furthermore, among
Leuven men older than 60 years, a number of significant
associations emerged that were not present in the unstrat-
ified analysis. There was a positive association between
bioE2 and cortical BMC at the 50% site and total BMD at
the 4% site. There were positive associations also between
bioT and (1) cortical BMC and stress strain index at the
50% site and (2) total area at the 4% site.
Influence of threshold level of bioavailable oestradiol
The median bioE2 in men (both centres combined) over
60 years was 51 pmol/L. Among the Leuven men, after
adjusting for age, height, and weight there was a significant
association between bioE2 and cortical BMD at the 50%
site among those above and below this threshold. The
magnitude of effect associated with trabecular BMD at the
4% site was broadly similar among those above and below
the threshold, but because of smaller numbers neither
association was statistically significant, see Table 6. There
was no association between bioE2 and BMD in either
compartment in Manchester men.
Discussion
Our data confirm evidence of age-related change at the
midshaft radius in cortical BMD and BMC, cortical
thickness and medullary area in middle-aged and elderly
men. Among older Leuven men oestrogen appeared to play
a role in maintaining BMD. BioT had no effect on BMD,
but may influence bone health through an effect on muscle
mass and bone area.
Our data confirm that there is lower BMC, thinner
cortex and larger medullary area at the radial diaphysis,
a n da l s oal o w e rm u s c l ea r e ai n ageing men. Despite the
lower BMC and muscle area with ageing it is possible
bone strength is maintained through periosteal apposi-
tion (indicated by marginally g r e a t e rb o n ea r e ai no l d e r
men). These data are consistent with those previously
reported at the distal site, with loss of trabecular and
total BMD [29] and a gain of bone on the periosteal
surface. The periosteal apposition at this site has been
s h o w nt om a i n t a i ns t r e n g t ha n dm a yb eo n er e a s o nw h y
the incidence of forearm fracture is lower in men (than
women) [30]. Taking muscle area as a surrogate for
loading, it is plausible that the small adaptations in bone
geometry can maintain strength to the level required for
reduced loading from muscles.
Evidence from observational and clinical studies support
the view that oestrogen is the most important sex steroid
in determining bone mass in men [7–12]. Our finding of
a positive relationship between E2 and BMD at both the
4% and 50% sites in the Leuven men is consistent with
this view. The association with bioE2 was stronger in the
older, than the younger, men which would be consistent
with a lower level of bioavailable hormone in older age.
Khosla et al. reported evidence of a threshold level of
bioE2 (30 pM) above which no association with oestrogen
was observed in cortical BMD, but not trabecular, bone at
a range of skeletal sites (femoral neck, distal radius, and
distal tibia) [14]. The threshold used, defined as the
Table 4 Influence of bioavailable testosterone and oestradiol on
pQCT parameters at the radius: by centre
Manchester Leuven
β co-efficient
a (95% CI) β co-efficient
a (95% CI)
Midshaft radius
Cortical BMD
BioT −0.427 (−2.505, 1.651) 0.583 (−1.354, 2.519)
BioE2 −0.006 (−0.237, 0.225) 0.393 (0.167, 0.618)*
Cortical BMC
BioT 0.235 (−0.676, 1.145) 0.812 (−0.009, 1.633)
BioE2 −0.056 (−0.157, 0.046) 0.094 (−0.002, 0.190)
Total area
BioT 0.140 (−0.934, 1.214) 0.511 (−0.590, 1.612)
BioE2 −0.072 (−0.191, 0.047) −0.107 (−0.236, 0.022)
Cortical thickness
BioT −0.002 (−0.026, 0.023) 0.018 (−0.004, 0.040)
BioE2 −0.001 (−0.004, 0.002) 0.004 (0.001, 0.006)*
Medullary area
BioT 0.028 (−0.840, 0.896) −0.160 (−1.145, 0.825)
BioE2 −0.030 (−0.127, 0.066) −0.156 (−0.272, −0.040)*
Stress strain index
BioT 1.090 (−2.139, 4.319) 2.541 (−0.730, 5.812)
BioE2 −0.184 (−0.543, 0.175) −0.106 (−0.485, 0.274)
CSMA
b
BioT 4.020 (−25.383, 33.424) 31.382 (7.565, 55.198)*
BioE2 −2.073 (−5.334, 1.188) 1.099 (−1.733, 3.931)
Distal radius
Total density
BioT 0.288 (−3.397, 3.974) −0.472 (−3.261, 2.317)
BioE2 0.248 (−0.161, 0.656) 0.259 (−0.069, 0.586)
Total area
BioT −0.295 (−2.994, 2.403) 3.241 (−0.107, 6.590)
BioE2 −0.313 (−0.611, −0.015)* 0.134 (−0.263, 0.531)
Trabecular density
BioT 0.590 (−2.043, 3.224) 0.399 (−1.742, 2.540)
BioE2 0.087 (−0.206, 0.379) 0.316 (0.064, 0.568)*
*p<0.05
aAdjusted for age, height, and weight
bCross-sectional muscle area
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u s e di no u rs t u d y( 5 1p m o l / L )w h i c hw a sb a s e do nm a s s
spectrometry measurements. Our data do not support these
observations of a threshold effect of bioE2 on cortical
bone.
The current view is that testosterone acts on bone
primarily via aromatisation to estrogens. There is some
evidence, at least in rats, that T may increase periosteal
apposition (and thereby increase total area), and certainly in
adolescents T increases periosteal growth. Szulc et al. using
data from DXA, suggested an increase in periosteal
apposition with age though not via an action of T [15,
31]. In contrast, Khosla et al. found an inverse association
in men with higher levels of T linked with reduced bone
area [14]. Our results (both centres) showed no significant
change in bone area with increasing testosterone at the 50%
site though there was a positive association at the 4% site
among the older Leuven men.
One of the intriguing findings was the differences in the
absolute pQCT parameters between the two centres and the
Table 5 Influence of bioavailable testosterone and oestradiol on pQCT parameters at the radius: by age and centre
Manchester Leuven
Age < 60 Age ≥ 60 Age < 60 Age ≥ 60
β co-efficient
a (95% CI) β co-efficient
a (95% CI) β co-efficient
a (95% CI) β co-efficient
a (95% CI)
Midshaft radius
Cortical BMD
BioT −1.282 (−3.559, 0.994) 0.336 (−3.232, 3.905) −1.631 (−4.039, 0.778) 3.117 (−0.072, 6.305)
BioE2 −0.046 (−0.319, 0.228) 0.030 (−0.337, 0.397) 0.107 (−0.182, 0.396) 0.699 (0.348, 1.050)*
Cortical BMC
BioT −0.116 (−1.233, 1.001) 0.513 (−0.943, 1.970) 0.031 (−1.104, 1.166) 1.818 (0.576, 3.059)*
BioE2 −0.146 (−0.278, −0.014)* 0.013 (−0.137, 0.163) 0.006 (−0.126, 0.137) 0.198 (0.057, 0.340)*
Total area
BioT 0.635 (−0.858, 2.127) −0.341 (−1.884, 1.201) 0.147 (−1.371, 1.665) 1.170 (−0.508, 2.848)
BioE2 −0.085 (−0.264, 0.093) −0.052 (−0.211, 0.106) −0.075 (−0.250, 0.100) −0.127 (−0.319, 0.064)
Cortical thickness
BioT −0.014 (−0.045, 0.017) 0.008 (−0.029, 0.044) 0.005 (−0.024, 0.034) 0.035 (−0.002, 0.071)
BioE2 −0.003 (−0.006, 0.001) −0.050 (−0.184, 0.085) 0.002 (−0.002, 0.005) 0.006 (0.002, 0.010)*
Medullary area
BioT 0.578 (−0.559, 1.715) −0.437 (−1.746, 0.872) −0.044 (−1.269, 1.181) −0.153 (−1.803, 1.496)
BioE2 0.010 (−0.127, 0.147) −0.050 (−0.184, 0.085) −0.074 (−0.220, 0.071) −0.239 (−0.424, −0.054)*
Stress strain index
BioT 2.103 (−2.304, 6.511) −0.177 (−4.914, 4.559) −0.580 (−5.335, 4.174) 6.186 (1.526, 10.846)*
BioE2 −0.344 (−0.870, 0.183) −0.053 (−0.540, 0.434) −0.250 (−0.789, 0.288) 0.078 (−0.461, 0.617)
CSMA
b
BioT 27.979 (−14.973, 70.931) −25.644 (−65.546, 14.257) 20.499 (−14.140, 55.137) 49.118 (15.313, 82.922)*
BioE2 −1.363 (−6.531, 3.806) −3.183 (−7.279, 0.913) 2.933 (−1.173, 7.040) −0.489 (−4.405, 3.427)
Distal radius
Total density
BioT −3.349 (−8.094, 1.396) 3.623 (−2.008, 9.255) −1.617 (−5.374, 2.140) 1.331 (−3.019, 5.680)
BioE2 0.223 (−0.347, 0.794) 0.238 (−0.343, 0.818) −0.086 (−0.533, 0.360) 0.639 (0.156, 1.121)*
Total area
BioT 1.536 (−2.117, 5.188) −2.362 (−6.361, 1.636) 0.772 (−3.620, 5.165) 6.111 (0.783, 11.440)*
BioE2 −0.355 (−0.790, 0.080) −0.261 (−0.672, 0.150) 0.354 (−0.163, 0.871) −0.106 (−0.719, 0.508)
Trabecular density
BioT −1.191 (−4.465, 2.083) 2.566 (−1.640, 6.772) 0.588 (−2.052, 3.228) 0.136 (−3.412, 3.685)
BioE2 0.104 (−0.289, 0.497) 0.092 (−0.342, 0.526) 0.200 (−0.115, 0.516) 0.420 (0.023, 0.817)*
*p<0.05
aAdjusted for age, height, and weight
bCross-sectional muscle area
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were recruited using the same methods and were from a
similar socioeconomic background. Removing subjects (n=
18) who were taking medications known to influence sex
steroid levels did not change the results. Further adjustment
for smoking and physical activity had no effect on these
relationships. The lower total BMD and larger bone area in
Leuven at the 4% site may in part be related to the slightly
different and more distal slice location used at the two
centres. It is unlikely, however, that this difference in
protocol explains centre differences at the 50% site due to
the more homogenous structure of the radius at this
anatomical site. It is therefore likely that other explanations,
including genetic and environmental factors, play a role in
these Manchester–Leuven skeletal and hormone differ-
ences. Genetic factors are known to influence both bone
mass and structure at the radius. Data from family and twin
studies suggest that genetic factors explain about 50% of
the variation in the radius total and trabecular vBMD, and
up to 40% of cortical vBMD [32, 33]. In addition, a large
proportion of the variation in geometric parameters such as
radius cross-sectional area (27%) and cortical thickness
(51%) are also attributable to genetic factors [33]. Varia-
tions in other skeletal parameters across Europe have
previously been reported [34]; however, to the best of our
knowledge, there are no data concerning pQCT parameters.
We cannot explain the variation in findings in relation to
the associations between bone parameters and sex hor-
mones, other than the slight difference in protocol using
pQCT which we feel would be unlikely to explain the
variation. The similarity in rate of change with age for the
skeletal parameters in both centres provides some construct
validity to these measures.
The strength of our study was that it was population
based and used pQCT measurements to obtain information
not only on bone density but also bone morphology. There
are some limitations which need to be considered when
interpreting the results. The response rate for participation
in the study was 45% [20]. Those who participated may
have differed with respect to bone health and/or sex
hormone status than those who did not participate.
However, the main findings, in relation to the sex steroid
levels were based on internal comparisons among respond-
ers and so selection factors are unlikely to have had an
important effect. One of the key factors in designing the
study was to ensure standardisation of the study instruments
used in the different participating centres. Hormone
measurements were performed in a central reference
laboratory to minimise assay variability. The same pQCT
scanner type and model was used in each centre and after
testing scanner differences with the EFP, no cross-
calibration was necessary. There was a small difference in
the 4% and 50% site location between centres, Leuven
being 1–2 mm more distal in position than Manchester, as
evidenced by a larger radial area and a lower total BMD in
Leuven compared to Manchester. This emphasizes the need
to have very precise and detailed protocols, including an
image of the position of the reference line, for performing
single-slice pQCT in multiple centres; quite large differ-
ences in the measured parameters can be observed in the
4% site, even in adjacent slices [35]. Although this may
explain differences in BMD and area at the 4% site between
centres, it is unlikely to affect the relationship between
these parameters and sex hormones at the 50% site. Our
study was cross-sectional: to determine true age-related
changes in bone health prospective data are needed. The
results were also obtained from a predominantly Caucasian
European population so cannot be extrapolated beyond this
setting.
In conclusion, there is evidence of age-related change at
the midshaft radius in cortical BMD and BMC, cortical
thickness and medullary area in middle-aged and elderly
European men. Among older men, bioE2 may play a role in
maintaining cortical and trabecular BMD. BioT has no
effect on BMD but may influence bone health through an
effect on muscle mass and bone area.
Table 6 Influence of bioavailable oestradiol on BMD at the radius in Leuven, Belgium (≥60 years): by median bioavailable oestradiol level
Bioavailable oestradiol (pmol/L)
BioE2 < 51 pmol/L BioE2 ≥ 51 pmol/L Overall
β co-efficient
a (95% CI) β co-efficient
a (95% CI) β co-efficient
a (95% CI)
Midshaft radius
Cortical BMD (mg/cm
3) 1.550 (0.584, 2.516)* 0.698 (0.059, 1.338)* 0.699 (0.348, 1.050)*
Distal radius
Total density (mg/cm
3) 0.020 (−1.340, 1.380) 0.783 (−0.079, 1.645) 0.639 (0.156, 1.121)*
Trabecular density (mg/cm
3) 0.410 (−0.740, 1.561) 0.516 (−0.156, 1.187) 0.420 (0.023, 0.817)*
*p<0.05
aAdjusted for age, height, and weight
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